卡瑞利珠单抗联合白蛋白结合型紫杉醇+替吉奥治疗胰腺癌的疗效  

Effect of camrelizumab combined with albumin-bound paclitaxel+S-1 in the treatment of pancreatic cancer

作　　者：魏晓辉 苏智祥 张燕军 刘爱琴 王云梅 侯银银 WEI Xiaohui;SU Zhixiang;ZHANG Yanjun;LIU Aiqin;WANG Yunmei;HOU Yinyin(Third Department of Internal Medicine,Shaanxi Provincial Cancer Hospital,Xi’an 710061,Shaanxi,China;Department of Medical Oncology,Shaanxi Provincial People’s Hospital,Xi’an 710068,Shaanxi,China)

机构地区：[1]陕西省肿瘤医院内三科,西安710061 [2]陕西省人民医院肿瘤内科,西安710068

出　　处：《癌症进展》2023年第22期2467-2470,共4页Oncology Progress

基　　金：陕西省重点研发计划项目(2022SF-261)。

摘　　要：目的 探讨卡瑞利珠单抗联合白蛋白结合型紫杉醇+替吉奥治疗胰腺癌的疗效。方法 依据治疗方式的不同将101例胰腺癌患者分为对照组(n=49)和观察组(n=52),对照组患者给予白蛋白结合型紫杉醇+替吉奥治疗,观察组患者给予卡瑞利珠单抗联合白蛋白结合型紫杉醇+替吉奥治疗。比较两组患者的近期疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、不良反应发生情况及生存情况。结果观察组患者的疾病控制率为67.31%,高于对照组患者的42.86%,差异有统计学意义(P<0.05)。治疗后,两组患者血清CEA、CA19-9水平均低于本组治疗前,观察组患者血清CEA、CA19-9水平均低于对照组。差异均有统计学意义(P<0.05)。两组患者疲乏、胃肠不适、周围神经毒性、白细胞减少、血小板减少、肝功能减退发生率比较,差异均无统计学意义(P>0.05)。两组患者3个月生存率比较,差异无统计学意义(P>0.05),观察组患者6个月生存率高于对照组,差异有统计学意义(P<0.05)。结论 卡瑞利珠单抗联合白蛋白结合型紫杉醇+替吉奥可提高胰腺癌患者的近期疗效和6个月生存率,且安全性高。Objective To investigate the efficacy of camrelizumab combined with albumin-bound paclitaxel+S-1 in the treatment of pancreatic cancer.Method A total of 101 patients with pancreatic cancer were divided into control group(n=49) and observation group(n=52) based on different treatment methods.Patients in the control group were treated with albumin-bound paclitaxel+S-1,and patients in the observation group were treated with camrelizumab combined with albumin-bound paclitaxel+S-1.The short-term efficacy,tumor markers [carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],adverse events,and survival were compared between the two groups.Result The disease control rate in the observation group was 67.31%,which was higher than 42.86% in the control group,and the difference was statistically significant(P<0.05).After the treatment,the serum CEA and CA19-9 levels of the two groups were lower than those before the treatment,the serum CEA and CA19-9 levels of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidence of fatigue,gastrointestinal discomfort,peripheral neurotoxicity,leukopenia,thrombocytopenia,and hypohepatia between the two groups(P>0.05).There was no statistically significant difference in the three-month survival of the two groups(P>0.05).The six-month survival rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Camrelizumab combined with albuminbound paclitaxel+S-1 could improve the short-term efficacy and six-month survival rate of patients with pancreatic cancer with high safety.

关 键 词：胰腺癌 卡瑞利珠单抗 白蛋白结合型紫杉醇 替吉奥 

分 类 号：R735.9[医药卫生—肿瘤]